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I. Theoretical background and aims of the dissertation 
 
Iran, as a developing country, is an upper middle-income country located in the 
southwest of Asia – the Middle East. Based on the latest reports of the World Bank, its 
population is 79.1 million people, its GDP (current US$) is 393.7 billion (year 2015), 
and its total expenditure on health is 6.9 percent of GDP (year 2014). The Iranian 
health care financing system is organized through a number of public and non-public 
insurance schemes. Access to services and choice of provider is determined largely by 
the type of insurance coverage.  
 
Iran has one of the first national Health Technology Assessment program, established 
in 2007, in the Eastern Mediterranean Region. Health technology assessment (HTA) is 
a form of policy research that systematically examines the short- and long-term 
consequences, in terms of health and resource use, of the application of a health 
technology, a set of related technologies or a technology related issue. HTA involves 
health economic evaluation that requires input data considering local aspects such as 
characteristics of the health care system, clinical practice, patients’ clinical status and 
health-related quality of life (HRQOL), individual and societal preferences and costs 
in a given country. HTA has been introduced in Iran, however country-specific input 
data both HRQOL and cost for health economic evaluation are often missing. 
 
For HRQOL research, it is fundamental to understand people’s notion on health. The 
concept of health has been dynamically changing by rise of new needs and diversity in 
human preferences. Also by improvement of life expectancy from the beginning of the 
20th century, the concept of health for the person and the society has evolved. 
Advancements in science and technology have made this possible and have changed 
human needs. The fear of dying has changed to dedication to survival and living 
healthier in a better quality of life for a longer time. Hence the importance of HRQOL 
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in determining the burden of a disease as well as the value of healthcare interventions 
has increased. 
 
Psoriasis is a chronic inflammatory disease affecting approximately 2% of the 
population globally. It represents a social and financial burden for patients and the 
healthcare system. Patients often suffer from disfigurement and from social 
stigmatization. Because the disease is usually persistent, patients usually need lifelong 
care, which also means a lifetime of expenses. Several questionnaires have been used 
to measure HRQOL in patients with psoriasis in Iran. However, to our knowledge 
there cannot be found any studies in the literature that assessed HRQOL of psoriasis 
patients with the EQ-5D, a preference-based tool that can provide utility data for 
quality-adjusted life year (QALY) calculations in cost-effectiveness analyses. 
Furthermore, there has not been published any cost-of-illness study in psoriasis from 
Iran or the Middle East region. Comparison of the findings in Iran with other countries 
can provide a basis for analyses of transferability of health economic evaluations. 
 
The thesis involves three major research topics, and the structure of the chapters 
follows these points: 
1. Health policy and Health Technology Assessment in Iran 
2. An empirical investigation into the concept of health 
3. Health-related quality of life and cost-of-illness of psoriasis in Iran 
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I.1 Objectives 
 
I.1.1 Health policy and Health Technology Assessment (HTA) in Iran 
(1) To provide an overview on the health system and healthcare financing in Iran 
with special focus on the development of HTA. 
I.1.2 An empirical investigation into the concept of health 
(1) To explore laymen’s opinions concerning the everyday notions of health. 
I.1.3 Health-related quality of life and cost-of-illness of psoriasis in Iran 
(1) To measure HRQOL of psoriasis patients in Iran with the general measure of 
EQ-5D and several disease-specific instruments. 
(2) To compare HRQOL of psoriasis patients to the age-matched general 
population in Iran. 
(3) Mapping EQ-5D index scores and EQ visual analogue scale (EQ VAS) 
scores from Dermatology Life Quality Index (DLQI) to provide utility values 
for economic evaluations. 
(4) To estimate annual per patient direct and indirect costs associated with 
psoriasis in Iran from a societal perspective. 
(5) To compare HRQOL and cost-of-illness in patients with psoriasis between 
Iran and Hungary. 
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II. Methodology   
 
II.1 Review on the health policy and HTA in Iran 
Characteristics of the health status of the population, healthcare system, healthcare 
financing system, health insurance system and HTA in Iran are reviewed and 
discussed based on the available literature. 
II.2 A survey exploring the importance of a set of factors in the concept of 
health 
In a cross-sectional survey 34 factors usually associated with the domain of health 
according to the literature were listed. Participants were asked to rate the importance 
of each factor in respect of health in general and also to add factors which they think 
are important. The degree of importance was measured on a Likert-type scale from 0 
to 6 (most irrelevant, irrelevant, not at all relevant, neutral, less relevant, relevant, and 
most relevant), and responses were scored from 1 to 7. Scoring of each factor was 
calculated by counting how many times participants marked each response level to 
each factor, then the total number of each factor was multiplied by the score we gave 
to each degree, and finally we add up all the numbers. The formula is: (numbers 
choosing most irrelevant x 1) + (numbers choosing irrelevant x 2) + (numbers 
choosing not at all relevant x 3) + (numbers choosing neutral x 4) + (numbers 
choosing less relevant x 5) + (numbers choosing relevant x 6) + (numbers choosing 
most relevant x 7). Finally, factors were sorted in descending order in the basis of the 
sums explained above. 
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II.3 Cross-sectional survey to assess health-related quality of life and cost-of-
illness of patients with psoriasis in Iran  
A cross-sectional questionnaire survey including 262 patients has been carried out. 
Overall, 200 patients from Hungary and 62 from Iran enrolled to the study. The 
Iranian study was performed from May to August 2013 at Moradi Skin Laser Clinic in 
Shiraz, Iran. We used a questionnaire that incorporated self-designed items and 
validated HRQOL and disease severity measures (Balogh et al., 2014, Heredi et al., 
2014). The questionnaire consisted of two parts; the first was filled out by the patients 
and the second by their dermatologist. HRQOL was assessed by EQ-5D, EQ VAS and 
DLQ). All the patients were managed by the same dermatologist who provided data 
on clinical type of psoriasis, psoriasis treatment in the last 12 months, and moreover, 
completed the Psoriasis Area Severity Index (PASI). 
II.3.1 Outcome measures 
EQ-5D questionnaire 
In our study, the validated Farsi version of the EQ-5D was administered. The EQ-5D 
consists of two pages - the EQ-5D descriptive system and the EQ VAS. The EQ-5D 
descriptive system comprises of the following 5 dimensions: mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression) (EuroQol Group, 1990). Each of 
these dimensions can be rated as 1 (no problems), 2 (some problems) or 3 (extreme 
problems). Due to absence of local value set in Iran, the UK weights were applied to 
calculate EQ-5D scores (i.e. utilities) that can range from -0.594 to +1, with higher 
scores referring to better HRQOL (Dolan, 1997). EQ-5D is accompanied by a visual 
analogue scale (EQ VAS) on which patients are asked to provide a self-assessment of 
their own health in a range from 0 (worst imaginable health state) to 100 (best 
imaginable health state). 
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Dermatology Life Quality Index (DLQI) 
Dermatology Life Quality Index (DLQI) is the most commonly used dermatology-
specific HRQOL questionnaire (Finlay&Khan, 1994). It consists of 10 questions 
covering symptoms, feelings, daily activities, leisure, work and school, personal 
relationships and treatment side effects that assess patients’ perception of the impact 
of skin condition of their HRQOL last week. Each question is scored on a 4-point 
Likert scale (0, not at all/not relevant; 1, a little; 2, a lot; 3, very much). DLQI score is 
calculated by summing up the score of each question and therefore, total scores range 
between 0 (least impact on HRQOL) and 30 (maximum impact on HRQOL). 
II.3.2 Costing 
The cost calculation was performed from societal perspective based on resource 
utilization data provided by the patients and their dermatologist in the questionnaire. 
Data were collected about direct and indirect costs (productivity loss). Official unit 
costs of the Iranian Ministry of Health were applied, where available. Timeframe of 
the cost analysis was 12 months, and the year of costs was 2016. 
Direct costs 
Data were collected from patients on the number of GP visits in the past one month, 
the number of dermatologist visits in the past three months and the number of 
hospitalizations over the past 12 months. According to the Iranian General Physicians’ 
Association, the cost of a GP visit and a dermatologist outpatient visit were €5.34 and 
€8.21, respectively. The daily average cost of hospitalization was considered at a 
public hospital rate (€45.95/day). On average fourteen days of inpatient stays were 
calculated for each hospitalization.  
The patients’ dermatologist provided data on the treatments applied in the past 12 
months. Costs of drugs and topical treatments (i.e. ointments) were based on official 
pharmacy list prices. Where multiple generic products were available, the drug with 
the lowest price was considered. Furthermore, patients answered questions about spa 
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and a neuropath visits or any other treatments/services used, and also indicated the 
monthly amount payed for these. 
To estimate costs of informal care, patients were asked to indicate how many hours of 
help they receive from informal caregivers such as family members or friends on a 
weekly average. Cost of informal care was calculated at a rate of €3.42/hour. 
Indirect costs 
The costs of productivity loss due to psoriasis were estimated by employing the 
Human Capital Approach based on patients’ responses on the Work Productivity and 
Activity Impairment questionnaire (WPAI) (Reilly et al., 1993). Psoriasis patients 
indicated the hours they actually worked in the past week, the hours missed by cause 
of psoriasis and other reasons and indicated the degree to which psoriasis affected 
productivity while working on an 11-point rating scale. Both costs of absenteeism 
(working hours missed due to psoriasis) and presenteeism (reduced productivity while 
at work due to psoriasis) were estimated. The average gross hourly wage (€3.74/hour) 
was applied for the cost calculation. 
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III. Main results 
 
III.1 Health policy characteristics and development of HTA in Iran 
The total population of the Islamic Republic of Iran is dynamically growing, as it 
increased by 10 million between 2000 and 2011 and was 79,109,000 in 2015. A 
dominance of age-group 25-54 years can be observed (47.6%) indicating a typically 
young population. Life expectancy at birth is increasing and it was 72.1 years for 
males and 74.6 years for females in 2011. The leading causes of death are non-
communicable diseases, namely ischaemic heart disease and cerebrovascular diseases. 
The most frequent health problems causing disability are low back and neck pain, 
depressive disorders, sense organ diseases, and diabetes. Skin disorders are in 5th place 
in the causes of disability.  
The Iran health system consists of both public and private sectors, and currently all 
Iranians have access to a government-supported health insurance system. However, 
due to the lack of sufficient resources in public health sectors and national health 
insurance schemes, in the past years and up to 2012, out-of-pocket payments of 
patients have substantially increased, it was 55% in 2008 (although the Iranian 
Development Plan set the goal for out-of-pocket payment to as low as 30% in 2008) 
and has topped to over 81.3% of the costs of medical services. 
Government pays for general revenue financing health care. General revenue 
financing of health care mostly gives primary health care (PHC) to the people and 
focuses on several secondary care services, such as expensive-to-manage diseases. In 
addition to that, public hospitals’ infrastructure is mostly paid out of government 
general revenue. Medicine production benefits from significant government subsidies.  
Social health care insurance covers around 90% of the population, and it focuses on 
non-PHC 'treatment' services, which includes most ambulatory, diagnostic and 
hospital services. The number of services they provide varies depending on the service 
and setting, and to some extent on who is the insurer. However, an important share of 
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health care bill is paid by people as out-of-pocket payments at the time of service 
utilization. Total health expenditure has increased very rapidly in the past decade, the 
per capita health expenditure has risen from $68 in 1995 to $229 in 2000 to $351 in 
2014.  
HTA began its activities as a secretariat in the Deputy of Health in 2007 in Iran and it 
continued as a Health Technology Assessment Office at the Management of Health 
Technology Assessment, Standardization, and Tariff at the Deputy of curative affairs 
of Ministry of Health and Medical Education (MoHME) in the beginning of 2010 with 
structurally enhanced objectives and goals to promote evidence based policy making. 
Between 2007 and 2010 altogether 22 HTA evaluations were conducted in Iran, 14 of 
which focused on medical equipment and eight pharmaceutical drug-related HTA 
were completed. These HTAs were funded through governmental budgets. Between 
2010-2015 more than 50 projects were conducted in various clinical fields and were 
used to inform Health Transformation Plan. Nonetheless, reimbursement does not 
depend on the results of the HTA. Further research is needed on how to increase the 
usefulness and efficacy of the HTA-backed decision making in Iran. 
III.2 Laymen’ opinion on the concept of health 
Survey questionnaires were completed by a convenience sample of 105 participants 
(66.7% female) with mean age of 31 (SD 9.1; minimum: 19, maximum: 63) years. 
The highest education level was as follows: 2 % had completed secondary school, 
45.7 % had a Bachelor’s degree, 35.2% a Master’s degree, 13.3% a PhD and 3.8% 
others. 
The five most relevant factors in the concept of health were (scores): Positive 
emotional feeling (659), Optimism (633), Fitness, Goal and harmony (630), and Love 
(627), respectively, while the five most irrelevant factors were Machine-like (327), 
Religiousness and beliefs (380), Flow (382), Reproduction of society (415), and 
Beauty (440). Other important aspects of health, such as Discipline, Ability to relax, 
Innovativeness and Maturity, were placed by participants in the middle of our rank 
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order (scores were 539, 530, 527, 522, respectively). Participants added further 
relevant factors, namely no stress, patience, security, proper partner relations, 
education, healthy diet, social responsibility, motivation, loving animals, spiritual 
well-being, internal and external balance, faithful and reliable friends. The fact that 
people attach less importance to beauty in the concept of health may have implications 
for priority setting and in the evaluation of skin diseases, including psoriasis that 
affects physical appearance. 
III.3 Disease burden of psoriasis in Iran and comparisons with Hungary 
III.3.1 Patient characteristics 
Mean age of the Iranian psoriasis patients was 40.40 (SD 17.53, range 16-86), with 76 
% males. The mean disease duration was 13.60 (SD 11.37) years. In total, 66% of the 
patients were diagnosed with chronic plaque psoriasis followed by scalp psoriasis 
36%, palmoplantar involvement 27%, inverse 26%, guttate 19%, and nail psoriasis 19 
%. Overall, 48% of the patients used only topical therapy in the last 12 months, and 
39% received systemic non-biological therapy. 
III.3.2 Health-related quality of life and disease severity results 
Mean EQ-5D, EQ VAS, DLQI and PASI scores were 0.62 (SD 0.37), 60.18 (27.26), 
10.19 (SD 6.46) and 12.94 (SD 8.28), respectively. In terms of the five underlying 
dimensions of EQ-5D, 18%, 26%, 28%, 63%, and 63% marked having some or severe 
problem in mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression, respectively. 
III.3.3 Mapping EQ-5D index scores and EQ VAS scores from DLQI to provide 
utility values for economic evaluations 
Linear relationships of DLQI onto both EQ-5D and EQ-VAS were estimated: EQ-5D= 
0.88 – 0.02*DLQI (adjusted r2=0.213, F-test p<0.001), EQ-VAS= 80.14 – 1.98 * 
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DLQI (adjusted r2=0.206, F-test p<0.001). Thus, 1 point increase in the DLQI results 
in 0.02 point decrease in the EQ-5D and 1.98 points decrease in EQ VAS. The DLQI 
score explained 22.6% of variance of EQ-5D and 22 % of the variance of EQ-VAS. 
 
III.3.4 Comparison of EQ-5D results with the Iranian general population 
In Iran, an EQ-5D population norm was published in 2016 (Karyani et al., 2016). 
They surveyed overall 600 members of the general population who had health 
insurance in Tehran, Iran. The rate of reporting problems regarding mobility was 
approximately equal among psoriasis patients and the age-matched general population 
(40-49 years): 18% vs. 22%. In the other four dimensions, considerably more 
problems occurred among psoriasis patients (self-care 27% vs. 3%, usual activities 
27% vs. 9%, anxiety/depression 63% vs. 39%, pain/discomfort 63% vs. 38%). 
Whereas few members of the general population reported severe problems in any 
dimension, psoriasis patients more often had such problems; for example, 16% in 
anxiety depression and 13% in pain discomfort. 
III.3.5 Comparison of HRQoL findings between Iran and Hungary 
A comparison between the findings of Iranian and Hungarian studies is provided in 
Table 1. Iranian patients were, on average, 10 years younger. More than half of the 
Hungarian patients used systemic biological therapy in the last 12 months but none in 
the Iranian study. The Iranian patients were in a worse health status assessed by any 
outcome measure (EQ-5D, DLQI and PASI). 
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Table 1. Health-related quality of life and disease severity of Hungarian and 
Iranian patients 
Variables 
Iran 
(2016) 
Hungary 
(2012) 
This study 
(Balogh et 
al., 2014) 
N 62 200 
Age (mean, SD) 40.4 (17.5) 51.2 (12.9) 
Males % 76% 69% 
BMI (mean, SD) 
25.66 
(3.29) 
29.89 
(5.44) 
Disease duration (mean, SD) 
13.60 
(11.37) 
21.96 
(11.67) 
Health-related quality of life and disease severity 
(mean, SD) 
  
EQ-5D (-0.594 to 1) 0.62 (0.37) 0.69 (0.3) 
DLQI (0-30) 10 (6.5) 6.29 (7.3) 
PASI (0-72) 13 (8.3) 8.1 (10) 
Treatment (during the last 12 months)    
None or topical therapy 48% 18% 
Systematic non-biological 39% 31% 
Biological 0% 51% 
 
III.3.6 Cost-of-illness of psoriasis in Iran 
Total annual per patient cost of psoriasis in Iran in 2016 was €3,373 (SD €4,757) 
(Table 2). The shares of direct medical, direct non-medical and indirect costs were 
23%, 11% and 65% of the total costs, respectively. Hospitalizations were responsible 
for the majority of direct medical costs, which accounted for about one-fifth of the 
total per patient costs of psoriasis. Costs of drugs and ointments took less than 6% of 
direct medical costs. Informal care represented 11% of the total costs. The highest 
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costs were related to productivity loss. Total indirect costs amounted to €2,209, with a 
share of €700 (32%) and €1,509 (68%) between absenteeism and presenteeism, 
respectively. 
 
Table 2. Comparison of annual cost in psoriasis in Iran and Hungary 
Cost items 
Mean EUR (SD) 
Iran 
(2016) 
Hungary (2012)  
(Balogh et al., 2014) 
N=62 N=200 
TOTAL COSTS 3,373 9,254 
Direct medical costs 789 
(23%) 
7,595 (82%) 
GP visit  26 
(0.8%) 
22 (0.2%) 
Outpatient dermatologist visit 42 (1%) 36 (0.4%) 
Hospitalizations 674 
(20%) 
136 (1%) 
Topical and systemic non-biological therapy 46 (1%) 256 (3%) 
Biological therapy - 7,339 (79%) 
Spa 0.05 
(0.001%) 
- 
Other 0.36 
(0.01%) 
60 (0.7%) 
Direct non-medical costs 376 
(11%) 
148 (2%) 
Informal care 376 
(11%) 
117 (1%) 
Transportation N/A 31 (0.3%) 
Indirect costs (productivity loss) 2,209 
(65%) 
1,255 (14%) 
N/A = not applicable 
III.3.7 Conclusions 
This is the first study from Iran that assesses HRQOL of psoriasis patients with EQ-
5D and EQ VAS and the first cost-of-illness study in psoriasis patients. HRQOL 
impairment measured with either EQ-5D or EQ VAS was considerable; some or 
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severe problems were most frequently emerged in anxiety/depression and 
pain/discomfort dimensions. Psoriasis patients have significantly decreased HRQOL 
measured by the EQ-5D compared to the general public in Iran. Moreover, EQ-5D 
scores evaluated in this study provide country-specific data for cost-utility analyses. 
Annual total costs of psoriasis in Iran exceeded €3,000 per patient, which is 
considerably higher than that of diabetes, gastroesophageal reflux disease or irritable 
bowel syndrome. The major cost drivers were productivity loss, hospitalizations and 
informal care.  
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IV. Implications for practice  
 
Results of the research presented in this thesis have various economic and health 
policy implications for Iran. Although biological drugs have brought the potential to 
dramatically change the management of patients with psoriasis, in Iran, the access to 
biological treatment is limited, mostly due to the high costs of biological drugs. Lack 
of insurance coverage of the biological drugs can lead to economic problems for the 
patients in obtaining them. Private companies (not related to the state) import these 
kinds of medicines and due to the frequent change of the currency value, the price of 
imported drugs are fluctuating. I believe that our findings can contribute to the 
improvement of psoriasis care by highlighting that this chronic skin disease imposes a 
great burden on the individuals and has a significant economic impact to the society. 
Moreover, our study provides reliable input data for cost-effectiveness analyses that 
can support sustainable financing decisions and long-term health planning. Our 
experiences with adapting a disease burden survey from another country to Iran can 
serve as a useful experience for other clinical fields with lack of HRQOL and disease 
burden data. 
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